The corporate has obtained approval from the US Meals and Drug Administration (USFDA) to market its product, which is a generic model of Anacor Prescription drugs’ Kerydin Topical Resolution, Lupin mentioned in a press release.
The product might be manufactured on the firm’s Pithampur-based facility, it added.
Tavaborole Topical Resolution is an oxaborole antifungal indicated for the topical remedy of onychomycosis of the toenails resulting from Trichophyton mentagrophytes.
As per IQVIA MAT December 2020 information, Tavaborole Topical Resolution had annual gross sales of round USD 76 million within the US.